Dose efficacy study of two schedules of high-dose bolus administration of interleukin-2 and interferon alpha in metastatic melanoma

Phase II study of recombinant alpha-interferon in malignant melanoma.

Neefe, J R
Legha, S S
Markowitz, A
Salmon, S
Meyskens, F
Groopman, J
Campion, M
Evans, L

December 1990

Ninety-seven evaluable patients with measurable, advanced, malignant melanoma were treated with reco...

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma.

Silk, Ann W
Curti, Brendan
Bryan, Jennifer
Saunders, Tracie
Shih, Weichung
Kane, Michael P
Hannon, Phoebe
Fountain, Christopher B
Felcher, Jessica
Zloza, Andrew
Kaufman, Howard L
Mehnert, Janice M
McDermott, David F

January 2023

INTRODUCTION: High-dose interleukin-2 (HD IL-2) and pembrolizumab are each approved as single agents...

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Eggermont, A.M.M.
Suciu, S.
Santinami, M.
Testori, A.
Kruit, W.H.
Marsden, J.
Punt, C.J.A.
Sales, F.
Gore, M.
MacKie, R.
Kusic, Z.
Dummer, R.
Hauschild, A.
Musat, E.
Spatz, A.
Keilholz, U.

January 2008

Contains fulltext : 69569.pdf (publisher's version ) (Closed access)BACKGROUND: An...

Combination chemotherapy together with interferon-alpha (IFN-alpha) in metastatic melanoma (MM), a multicenter phase II study

Punt, C.J.A.
Jansen, R.L.H.
Vreugdenhil, A.
Mulder, P.H.M. de

January 1995

Contains fulltext : 21726___.PDF (publisher's version ) (Open Access

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

Keilholz, U.
Goey, S.H.
Punt, C.J.A.
Proebstle, T.M.
Salzmann, R.
Scheibenbogen, C.
Schadendorf, D.
Liénard, D.
Enk, A.
Dummer, R.
Hantich, B.
Geueke, A.-M.
Eggermont, A.M.M.

January 1997

Contains fulltext : 26097___.PDF (publisher's version ) (Open Access

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

Keilholz, U.
Punt, C.J.A.
Gore, M.
Kruit, W.
Patel, P.
Lienard, D.
Thomas, J.
Proebstle, T.M.
Schmittel, A.
Schadendorf, D.
Velu, T.
Negrier, S.
Kleeberg, U.R.
Lehman, F.
Suciu, S.
Eggermont, A.M.M.

January 2005

Contains fulltext : 49220schadendorf.pdf (publisher's version ) (Closed access)BAC...

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study

Punt, C.J.A.
Herpen, C.M.L. van
Jansen, R.L.H.
Vreugdenhil, A.
Muller, E.W.
Mulder, P.H.M. de

January 1997

Contains fulltext : 25471.PDF (publisher's version ) (Open Access

An open-label, randomized, multi-center study comparing the sequence of high dose aldesleukin (interleukin-2) and ipilimumab (yervoy) in patients with metastatic melanoma

Hasanov, Merve
Milton, Denái R
Sharfman, William H
Taback, Bret
Cranmer, Lee D
Daniels, Gregory A
Flaherty, Lawrence
Hallmeyer, Sigrun
Milhem, Mohammed

January 2021

Combination immunotherapy with sequential administration may enhance metastatic melanoma (MM) patien...

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

T. Eigentler
B. Weide
F. de Braud
G. Spitaleri
A. Romanini
A. Pflugfelder
R. Gonz&#225
A. Tasciotti
L. Giovannoni
K. Schwager
V. Lovato
M. Kaspar
E. Trachsel
H. Menssen
D. Neri
C. Garbe

January 2011

Purpose: L19-IL2 is an immunocytokine composed of an antibody fragment specific to the EDB domain of...

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

Keilholz, U.
Goey, S.H.
Punt, C.J.
Proebstle, T.M.
Salzmann, R.
Scheibenbogen, C.
Schadendorf, D.
Liénard, D.
Enk, A.
Dummer, R.
Hantich, B.
Geueke, A.M.
Eggermont, A.M.

January 1997

PURPOSE: The combination of interferon alfa-2a (IFN alpha) and high-dose interleukin-2 (IL-2) is act...

Is There A Role for Adjuvant High Dose Interferon in the Management of Melanoma

Sabel, Michael S.
Sondak, Vernon K.

January 2003

A look at the evidence supporting the use of high dose interferon in the adjuvant therapy of melanom...

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Eggermont, A.M.M.
Suciu, S.
MacKie, R.
Ruka, W.
Testori, A.
Kruit, W.
Punt, C.J.A.
Delauney, M.
Sales, F.
Groenewegen, G.
Ruiter, D.J.
Jagiello, I.
Stoitchkov, K.
Keilholz, U.
Lienard, D.

January 2005

Contains fulltext : 49192.pdf (publisher's version ) (Closed access)BACKGROUND: In...

Update on use of aldesleukin for treatment of high-risk metastatic melanoma

Amaria RN
Reuben A
Cooper ZA
Wargo JA

April 2015

Rodabe N Amaria,1 Alexandre Reuben,2 Zachary A Cooper,2,3 Jennifer A Wargo2,3 1Department of Melanom...

Research Article Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses

Benjamin Weide
Thomas K. Eigentler
Annette Pflugfelder
Henning Zelba
Er Martens
Graham Pawelec
Leonardo Giovannoni
Pier Adelchi Ruffini
Giuliano Elia
Dario Neri
Ralf Gutzmer
J€urgen C. Becker
Claus Garbe

October 2016

L19–IL2 is a recombinant protein comprising the cytokine IL2 fused to the single-chain monoclonal an...

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)

Patel, Sapna
Milhem, Mohammed
Hallmeyer, Sigrun
Daniels, Gregory
Cranmer, Lee
Taback, Bret
Flaherty, Lawrence
Aung, Sandra
Lowder, James
Sharfman, William

January 2014

Purpose: To investigate whether the sequence of HD IL-2 and a checkpoint inhibitor, Ipilimumab, will...

Phase II study of recombinant alpha-interferon in malignant melanoma.

Neefe, J R
Legha, S S
Markowitz, A
Salmon, S
Meyskens, F
Groopman, J
Campion, M
Evans, L

December 1990

Ninety-seven evaluable patients with measurable, advanced, malignant melanoma were treated with reco...

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma.

Silk, Ann W
Curti, Brendan
Bryan, Jennifer
Saunders, Tracie
Shih, Weichung
Kane, Michael P
Hannon, Phoebe
Fountain, Christopher B
Felcher, Jessica
Zloza, Andrew
Kaufman, Howard L
Mehnert, Janice M
McDermott, David F

January 2023

INTRODUCTION: High-dose interleukin-2 (HD IL-2) and pembrolizumab are each approved as single agents...

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Eggermont, A.M.M.
Suciu, S.
Santinami, M.
Testori, A.
Kruit, W.H.
Marsden, J.
Punt, C.J.A.
Sales, F.
Gore, M.
MacKie, R.
Kusic, Z.
Dummer, R.
Hauschild, A.
Musat, E.
Spatz, A.
Keilholz, U.

January 2008

Contains fulltext : 69569.pdf (publisher's version ) (Closed access)BACKGROUND: An...

Combination chemotherapy together with interferon-alpha (IFN-alpha) in metastatic melanoma (MM), a multicenter phase II study

Punt, C.J.A.
Jansen, R.L.H.
Vreugdenhil, A.
Mulder, P.H.M. de

January 1995

Contains fulltext : 21726___.PDF (publisher's version ) (Open Access

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

Keilholz, U.
Goey, S.H.
Punt, C.J.A.
Proebstle, T.M.
Salzmann, R.
Scheibenbogen, C.
Schadendorf, D.
Liénard, D.
Enk, A.
Dummer, R.
Hantich, B.
Geueke, A.-M.
Eggermont, A.M.M.

January 1997

Contains fulltext : 26097___.PDF (publisher's version ) (Open Access

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

Keilholz, U.
Punt, C.J.A.
Gore, M.
Kruit, W.
Patel, P.
Lienard, D.
Thomas, J.
Proebstle, T.M.
Schmittel, A.
Schadendorf, D.
Velu, T.
Negrier, S.
Kleeberg, U.R.
Lehman, F.
Suciu, S.
Eggermont, A.M.M.

January 2005

Contains fulltext : 49220schadendorf.pdf (publisher's version ) (Closed access)BAC...

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study

Punt, C.J.A.
Herpen, C.M.L. van
Jansen, R.L.H.
Vreugdenhil, A.
Muller, E.W.
Mulder, P.H.M. de

January 1997

Contains fulltext : 25471.PDF (publisher's version ) (Open Access

An open-label, randomized, multi-center study comparing the sequence of high dose aldesleukin (interleukin-2) and ipilimumab (yervoy) in patients with metastatic melanoma

Hasanov, Merve
Milton, Denái R
Sharfman, William H
Taback, Bret
Cranmer, Lee D
Daniels, Gregory A
Flaherty, Lawrence
Hallmeyer, Sigrun
Milhem, Mohammed

January 2021

Combination immunotherapy with sequential administration may enhance metastatic melanoma (MM) patien...

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

T. Eigentler
B. Weide
F. de Braud
G. Spitaleri
A. Romanini
A. Pflugfelder
R. Gonz&#225
A. Tasciotti
L. Giovannoni
K. Schwager
V. Lovato
M. Kaspar
E. Trachsel
H. Menssen
D. Neri
C. Garbe

January 2011

Purpose: L19-IL2 is an immunocytokine composed of an antibody fragment specific to the EDB domain of...

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

Keilholz, U.
Goey, S.H.
Punt, C.J.
Proebstle, T.M.
Salzmann, R.
Scheibenbogen, C.
Schadendorf, D.
Liénard, D.
Enk, A.
Dummer, R.
Hantich, B.
Geueke, A.M.
Eggermont, A.M.

January 1997

PURPOSE: The combination of interferon alfa-2a (IFN alpha) and high-dose interleukin-2 (IL-2) is act...

Is There A Role for Adjuvant High Dose Interferon in the Management of Melanoma

Sabel, Michael S.
Sondak, Vernon K.

January 2003

A look at the evidence supporting the use of high dose interferon in the adjuvant therapy of melanom...

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Eggermont, A.M.M.
Suciu, S.
MacKie, R.
Ruka, W.
Testori, A.
Kruit, W.
Punt, C.J.A.
Delauney, M.
Sales, F.
Groenewegen, G.
Ruiter, D.J.
Jagiello, I.
Stoitchkov, K.
Keilholz, U.
Lienard, D.

January 2005

Contains fulltext : 49192.pdf (publisher's version ) (Closed access)BACKGROUND: In...

Update on use of aldesleukin for treatment of high-risk metastatic melanoma

Amaria RN
Reuben A
Cooper ZA
Wargo JA

April 2015

Rodabe N Amaria,1 Alexandre Reuben,2 Zachary A Cooper,2,3 Jennifer A Wargo2,3 1Department of Melanom...

Research Article Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses

Benjamin Weide
Thomas K. Eigentler
Annette Pflugfelder
Henning Zelba
Er Martens
Graham Pawelec
Leonardo Giovannoni
Pier Adelchi Ruffini
Giuliano Elia
Dario Neri
Ralf Gutzmer
J€urgen C. Becker
Claus Garbe

October 2016

L19–IL2 is a recombinant protein comprising the cytokine IL2 fused to the single-chain monoclonal an...

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)

Patel, Sapna
Milhem, Mohammed
Hallmeyer, Sigrun
Daniels, Gregory
Cranmer, Lee
Taback, Bret
Flaherty, Lawrence
Aung, Sandra
Lowder, James
Sharfman, William

January 2014

Purpose: To investigate whether the sequence of HD IL-2 and a checkpoint inhibitor, Ipilimumab, will...

Phase II study of recombinant alpha-interferon in malignant melanoma.

Neefe, J R
Legha, S S
Markowitz, A
Salmon, S
Meyskens, F
Groopman, J
Campion, M
Evans, L

December 1990

Ninety-seven evaluable patients with measurable, advanced, malignant melanoma were treated with reco...

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma.

Silk, Ann W
Curti, Brendan
Bryan, Jennifer
Saunders, Tracie
Shih, Weichung
Kane, Michael P
Hannon, Phoebe
Fountain, Christopher B
Felcher, Jessica
Zloza, Andrew
Kaufman, Howard L
Mehnert, Janice M
McDermott, David F

January 2023

INTRODUCTION: High-dose interleukin-2 (HD IL-2) and pembrolizumab are each approved as single agents...

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Eggermont, A.M.M.
Suciu, S.
Santinami, M.
Testori, A.
Kruit, W.H.
Marsden, J.
Punt, C.J.A.
Sales, F.
Gore, M.
MacKie, R.
Kusic, Z.
Dummer, R.
Hauschild, A.
Musat, E.
Spatz, A.
Keilholz, U.

January 2008

Contains fulltext : 69569.pdf (publisher's version ) (Closed access)BACKGROUND: An...

Dose efficacy study of two schedules of high-dose bolus administration of interleukin-2 and interferon alpha in metastatic melanoma

Abstract

Extracted data

Dose efficacy study of two schedules of high-dose bolus administration of interleukin-2 and interferon alpha in metastatic melanoma

Abstract

Extracted data

Related items

Related items